Research programme: biosimilars - Lupin

Drug Profile

Research programme: biosimilars - Lupin

Alternative Names: Teriparatide biosimilar - Lupin

Latest Information Update: 02 May 2014

Price : $50

At a glance

  • Originator Lupin
  • Class Monoclonal antibodies; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammation; Rheumatoid arthritis; Viral infections

Most Recent Events

  • 02 May 2014 Preclinical trials in Viral infections in India (unspecified route)
  • 23 Apr 2014 Preclinical trials in Inflammation in India (SC)
  • 23 Apr 2014 Preclinical trials in Rheumatoid arthritis in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top